Bora Gurel

Citace

	Všechny	Od 2020
Citace	7047	4146
h-index	37	29
i10-index	60	51

1000

500

250

750

2009201020112012201320142015201620172018201920202021202220232024202538 89 173 214 284 294 308 392 343 339 369 530 771 832 852 986 149

Veřejný přístup

Zobrazit všechny

67 článků

0 článků

dostupné

nedostupné

Vychází ze zplnomocnění pro financování

Spoluautoři

Angelo M. De Marzo M.D., Ph.D.Professor of Pathology, Urology and Oncology, The Johns Hopkins University School of MedicineE-mailová adresa ověřena na: jhmi.edu
Johann de BonoInstitute of Cancer ResearchE-mailová adresa ověřena na: icr.ac.uk
William G. NelsonProfessor of Oncology, Johns Hopkins University School of MedicineE-mailová adresa ověřena na: jhmi.edu
Suzanne Carreirainstitute of cancer researchE-mailová adresa ověřena na: icr.ac.uk
Wei YuanInstitute of Cancer ResearchE-mailová adresa ověřena na: icr.ac.uk
William B. IsaacsProfessor of Urology and Oncology, Brady Urological Inst, Johns Hopkins Univ, School of MedicineE-mailová adresa ověřena na: jhmi.edu
Tamara LotanProfessor and Deputy Director for Research, Department of Pathology, Johns Hopkins UniversityE-mailová adresa ověřena na: jhmi.edu
Ana FerreiraAlunaE-mailová adresa ověřena na: eduttacademy.com.br
Michael Christoph HaffnerFred Hutchinson Cancer Research CenterE-mailová adresa ověřena na: fredhutch.org
Pasquale RescignoCandiolo Cancer Institute, FPO-IRCCS, Turin Italy; The Institute of Cancer Research (ICR), LondonE-mailová adresa ověřena na: ircc.it
Elizabeth A. PlatzProfessor, Department of Epidemiology, Johns Hopkins Bloomberg School of PublicE-mailová adresa ověřena na: jhu.edu
Toby C. Cornish, MD, PhDProfessor of Pathology, Medical College of WisconsinE-mailová adresa ověřena na: mcw.edu
Daniel RodriguesThe Institute of Cancer ResearchE-mailová adresa ověřena na: icr.ac.uk
Cheryl M KohJohns Hopkins University School of MedicineE-mailová adresa ověřena na: jhmi.edu
George SeedPost-Doctoral Fellow, The Institute of Cancer ResearchE-mailová adresa ověřena na: icr.ac.uk
Ines FigueiredoE-mailová adresa ověřena na: icr.ac.uk
"Mateus Crespo"The Institute of Cancer ResearchE-mailová adresa ověřena na: icr.ac.uk
George J Netto MDUniversity of Pennsylvania Perleman School of Medicine.E-mailová adresa ověřena na: pennmedicine.upenn.edu
"G. Steven Bova", "GS Bova", "George..."Tampere University School of Medicine and Health Technology","BioMediTech","Johns HopkinsE-mailová adresa ověřena na: telamon1.us
Martin J. AryeeAssociate Professor, Dept of Data Science, Dana Farber Cancer Institute & Dept of Pathology, HarvardE-mailová adresa ověřena na: ds.dfci.harvard.edu

Sledovat

Bora Gurel

The Institute of Cancer Research, London

E-mailová adresa ověřena na: icr.ac.uk - Domovská stránka

Uropathology Prostate Cancer Molecular Pathology Computerized Image Analysis Nephropathology


Název Seřadit podle citací Seřadit podle roku Seřadit podle názvu	Citace Citace	Rok
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements MC Haffner, MJ Aryee, A Toubaji, DM Esopi, R Albadine, B Gurel, ... Nature genetics 42 (8), 668-675, 2010	691	2010
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020	628	2020
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis B Gurel, T Iwata, CM Koh, RB Jenkins, F Lan, C Van Dang, JL Hicks, ... Modern Pathology 21 (9), 1156-1167, 2008	524	2008
PTEN protein loss by immunostaining: Analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients TL Lotan, B Gurel, S Sutcliffe, D Esopi, W Liu, J Xu, JL Hicks, BH Park, ... Clinical Cancer Research 17 (20), 6563-6573, 2011	408	2011
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer A Paschalis, B Sheehan, R Riisnaes, DN Rodrigues, B Gurel, C Bertan, ... European Urology, 2019	403	2019
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity S Yegnasubramanian, MC Haffner, Y Zhang, B Gurel, TC Cornish, Z Wu, ... Cancer research 68 (21), 8954-8967, 2008	358	2008
NKX3. 1 as a marker of prostatic origin in metastatic tumors B Gurel, TZ Ali, EA Montgomery, S Begum, J Hicks, M Goggins, ... The American journal of surgical pathology 34 (8), 1097-1105, 2010	345	2010
Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial B Gurel, MS Lucia, IM Thompson, PJ Goodman, CM Tangen, AR Kristal, ... Cancer Epidemiology Biomarkers & Prevention 23 (5), 847-856, 2014	298	2014
Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020	273	2020
Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy SR Denmeade, AM Mhaka, DM Rosen, WN Brennen, S Dalrymple, I Dach, ... Science translational medicine 4 (140), 140ra86-140ra86, 2012	257	2012
Targeting the p300/CBP axis in lethal prostate cancer J Welti, A Sharp, N Brooks, W Yuan, C McNair, SN Chand, A Pal, ... Cancer Discovery 11 (5), 1118-1137, 2021	186	2021
Prostate carcinogenesis: inflammatory storms JS de Bono, C Guo, B Gurel, AM De Marzo, KS Sfanos, RS Mani, J Gil, ... Nature Reviews Cancer 20 (8), 455-469, 2020	174	2020
Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene CM Koh, B Gurel, S Sutcliffe, MJ Aryee, D Schultz, T Iwata, M Uemura, ... The American journal of pathology 178 (4), 1824-1834, 2011	146	2011
Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats S Atasayar, H Gürer-Orhan, H Orhan, B Gürel, G Girgin, H Özgüneş Experimental and Toxicologic Pathology 61 (1), 23-32, 2009	128	2009
Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial S Carreira, N Porta, S Arce-Gallego, G Seed, A Llop-Guevara, D Bianchini, ... Cancer discovery 11 (11), 2812-2827, 2021	122	2021
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy ES Antonarakis, D Keizman, Z Zhang, B Gurel, TL Lotan, JL Hicks, ... Cancer 118 (24), 6063-6071, 2012	122	2012
Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization MC Haffner, C Weier, MM Xu, A Vaghasia, B Gürel, B Gümüşkaya, ... The Journal of pathology 238 (1), 31-41, 2016	112	2016
Loss of Nkx3. 1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia M Khalili, LN Mutton, B Gurel, JL Hicks, AM De Marzo, CJ Bieberich The American journal of pathology 176 (5), 2259-2268, 2010	101	2010
Advanced prostate cancer with ATM loss: PARP and ATR inhibitors A Neeb, N Herranz, S Arce-Gallego, S Miranda, L Buroni, W Yuan, A Athie, ... European Urology 79 (2), 200-211, 2021	99	2021
Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. B Gurel, T Iwata, CM Koh, S Yegnasubramanian, WG Nelson, ... Advances in anatomic pathology 15 (6), 319-331, 2008	95	2008

Systém momentálně nemůže danou operaci provést. Zkuste to znovu později.

Články 1–20

Citace za rok

Duplicitní citace

Sloučené citace

Přidat spoluautorySpoluautoři

Sledovat

Citace

Spoluautoři